Phase 2 Trial

BioRestorative Therapies, Inc. will present blinded data from a Phase 2 clinical trial of its hypoxic‑cultured mesenchymal stem cell product, BRTX‑100, at the 2026 Orthopaedic Research Society Annual Meeting on March 28. The study enrolled approximately 45 patients with chronic lumbar disc disease and is expected to demonstrate meaningful improvements in pain and function. A press release will follow the presentation to disclose the detailed results.